# The Sagittarius Trial

> **NCT06490536** · PHASE3 · RECRUITING · sponsor: **IFOM ETS - The AIRC Institute of Molecular Oncology** · enrollment: 700 (estimated)

## Conditions studied

- Colon Cancer Stage II
- Colon Cancer Stage III

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** Folinic acid
- **DRUG:** Fluorouracil
- **DRUG:** Temozolomide
- **DRUG:** Irinotecan
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Panitumumab

## Key facts

- **NCT ID:** NCT06490536
- **Lead sponsor:** IFOM ETS - The AIRC Institute of Molecular Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-22
- **Primary completion:** 2026-03-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06490536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06490536, "The Sagittarius Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06490536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*